April 4 (Reuters) - Boston Scientific Corp on Monday said it has temporarily stopped selling a newer version of its Watchman atrial fibrillation treatment in Europe due to a higher-than-expected rate of embolisms associated with the implant.
Read more
No comments:
Post a Comment